Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

#1277

Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)

Aim(s): We evaluated long-term efficacy and toxicity in 65 consecutive patients (pts) with P-NETs treated with a personalized activity of Lu-PRRT. We also evaluated the role of FDG PET as an independent prognostic factor in P-NET pts

Materials and methods: 65 consecutive pts with P-NETs were enrolled in a prospective study. Pts were treated with two different total activities (18.5GBq or 27.8 GBq) in 5 cycles on the basis of kidney function and bone marrow parameters. 59 pts underwent FDG PET before Lu-PRRT

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sansovini M

Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,

Keywords: PRRT, FDG-PET, P-NET,